Ascentage Pharma Group International (AAPG) Non-Current Deferred Tax Liability: 2022-2024

Historic Non-Current Deferred Tax Liability for Ascentage Pharma Group International (AAPG) over the last 3 years, with Dec 2024 value amounting to $1.7 million.

  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability fell 25.35% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year decrease of 25.35%. This contributed to the annual value of $1.7 million for FY2024, which is 84.31% down from last year.
  • As of FY2024, Ascentage Pharma Group International's Non-Current Deferred Tax Liability stood at $1.7 million, which was down 84.31% from $10.5 million recorded in FY2023.
  • In the past 5 years, Ascentage Pharma Group International's Non-Current Deferred Tax Liability ranged from a high of $10.5 million in FY2023 and a low of $1.7 million during FY2024.
  • Over the past 3 years, Ascentage Pharma Group International's median Non-Current Deferred Tax Liability value was $2.6 million (recorded in 2022), while the average stood at $4.9 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first surged by 305.22% in 2023, then crashed by 84.31% in 2024.
  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability (Yearly) stood at $2.6 million in 2022, then surged by 305.22% to $10.5 million in 2023, then tumbled by 84.31% to $1.7 million in 2024.